| Regulation of the polarity protein Par6 by TGFß receptors controls epithelial cell plasticity B Ozdamar, R Bose, M Barrios-Rodiles, HR Wang, Y Zhang, JL Wrana Science 307 (5715), 1603-1609, 2005 | 1136 | 2005 |
| High-throughput mapping of a dynamic signaling network in mammalian cells M Barrios-Rodiles, KR Brown, B Ozdamar, R Bose, Z Liu, RS Donovan, ... Science 307 (5715), 1621-1625, 2005 | 880 | 2005 |
| Regulation of planar cell polarity by Smurf ubiquitin ligases M Narimatsu, R Bose, M Pye, L Zhang, B Miller, P Ching, R Sakuma, ... Cell 137 (2), 295-307, 2009 | 356 | 2009 |
| The DNA methylation landscape of advanced prostate cancer SG Zhao, WS Chen, H Li, A Foye, M Zhang, M Sjöström, R Aggarwal, ... Nature genetics 52 (8), 778-789, 2020 | 231 | 2020 |
| FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ... Nature 571 (7765), 408-412, 2019 | 195 | 2019 |
| A role for the TGFβ-Par6 polarity pathway in breast cancer progression AM Viloria-Petit, L David, JY Jia, T Erdemir, AL Bane, D Pinnaduwage, ... Proceedings of the National Academy of Sciences 106 (33), 14028-14033, 2009 | 163 | 2009 |
| Degradation of RhoA by Smurf1 ubiquitin ligase HR Wang, AA Ogunjimi, Y Zhang, B Ozdamar, R Bose, JL Wrana Methods in enzymology 406, 437-447, 2006 | 97 | 2006 |
| Regulation of Par6 by extracellular signals R Bose, JL Wrana Current opinion in cell biology 18 (2), 206-212, 2006 | 95 | 2006 |
| ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis R Bose, WR Karthaus, J Armenia, W Abida, PJ Iaquinta, Z Zhang, ... Nature 546 (7660), 671-675, 2017 | 82 | 2017 |
| Income and spending patterns among panhandlers R Bose, SW Hwang CMAJ 167 (5), 477-479, 2002 | 57 | 2002 |
| Spectroscopic characterization by laser flash photolysis of electrophilic intermediates derived from 4-aminostilbenes. Stilbene “nitrenium” ions and quinone methide imines AR Bose, R, Ahmad, AP Dicks, KJ Kayser, RA McClelland Journal of the Chemical Society, Perkin Transactions 2, 1591-1600, 1999 | 33 | 1999 |
| Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. RR Aggarwal, S Luch Sam, VS Koshkin, EJ Small, FY Feng, ... Journal of Clinical Oncology 39 (15_suppl), 5053-5053, 2021 | 29 | 2021 |
| Genomic alteration burden in advanced prostate cancer and therapeutic implications MJ Ryan, R Bose Frontiers in Oncology 9, 1287, 2019 | 28 | 2019 |
| The 5-hydroxymethylcytosine landscape of prostate cancer M Sjöström, SG Zhao, S Levy, M Zhang, Y Ning, R Shrestha, A Lundberg, ... Cancer research 82 (21), 3888-3902, 2022 | 22 | 2022 |
| Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial R Aggarwal, S Starzinski, I de Kouchkovsky, V Koshkin, R Bose, J Chou, ... The Lancet Oncology 24 (11), 1266-1276, 2023 | 13 | 2023 |
| Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic … K Ogura, A Elkrief, AS Bowman, RP Koche, E de Stanchina, R Benayed, ... JCO precision oncology 6, e2200048, 2022 | 6 | 2022 |
| Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma patients treated with immune checkpoint inhibitors or enfortumab … T Jindal, L Zhang, P Deshmukh, K Reyes, E Chan, V Kumar, X Zhu, ... Clinical Genitourinary Cancer 21 (5), e394-e404, 2023 | 4 | 2023 |
| Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). DV Natesan, L Zhang, DY Oh, SP Porten, M Meng, R Pruthi, ... Journal of Clinical Oncology 39 (15_suppl), e16510-e16510, 2021 | 4 | 2021 |
| International SU2C/PCF Prostate Cancer Dream Team; Zheng D, Schultz N, Sawyers CL. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis R Bose, WR Karthaus, J Armenia, W Abida, PJ Iaquinta, Z Zhang, ... Nature 546 (7660), 671-675, 2017 | 4 | 2017 |
| TGFβ signal transduction C Silvestri, R Bose, L Attisano, JL Wrana Handbook of Cell Signaling, 521-532, 2010 | 4 | 2010 |
Jeff WranaSenior Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto; Professor, Dept. of Mol. Gen., U. ofVerified email at lunenfeld.ca
